The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer.

Conclusion: Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment. PMID: 30687403 [PubMed]
Source: Advances in Urology - Category: Urology & Nephrology Tags: Adv Urol Source Type: research